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A new analytical framework for verification of biomarkers of exposure to chemicals 1 
combining human biomonitoring and water fingerprinting   2 
Luigi Lopardo, Andrew Cummins, Axel Rydevik and Barbara Kasprzyk-Hordern*3 
Department of Chemistry, University of Bath, Bath BA2 7AY, UK 4 
 5 
Abstract 6 
Molecular epidemiology approaches in human biomonitoring are powerful tools that allow for 7 
verification of public exposure to chemical substances. Unfortunately, due to logistical difficulties and 8 
high cost, they tend to evaluate small study groups and as a result might not provide comprehensive 9 
large scale community-wide exposure data. Urban water fingerprinting provides a timely alternative to 10 
traditional approaches. It can revolutionise the human exposure studies as urban water represents 11 
collective community-wide exposure. Knowledge of characteristic biomarkers of exposure to specific 12 
chemicals is key to the successful application of water fingerprinting. This study aims to introduce a 13 
novel conceptual analytical framework for identification of biomarkers of public exposure to chemicals 14 
via combined human metabolism and urban water fingerprinting assay. This framework consists of: 15 
Step 1 - In vitro HLM/S9 assay; Step 2 – In vivo pooled urine assay; Step 3 - In vivo wastewater 16 
fingerprinting assay; Step 4 - Analysis with HR-MSMS; Step 5 - Data processing and Step 6 - Selection 17 
of biomarkers. The framework was applied and validated for PCMC (4-chloro-m-cresol), household 18 
derived antimicrobial agent with no known exposure and human metabolism data. Four new metabolites 19 
of PCMC (hydroxylated, sulphated/hydroxylated, sulphated PCMC and PCMC glucuronide) were 20 
identified using the in vitro HLM/S9 assay. But only one metabolite, sulphated PCMC, was confirmed 21 
in wastewater and in urine. Therefore, our study confirms that water fingerprinting is a promising tool 22 
for biomarker selection and that in vitro HLM/S9 studies alone, although informative, do not provide 23 
high accuracy results. Our work also confirms, for the first time, human internal exposure to PCMC.  24 
 25 
Introduction 26 
Antimicrobials are extensively used as additives in a broad range of personal care and consumer 27 
products to preserve the integrity of the products against biological agents, although their effectiveness 28 
against the potential hazard has been questioned 1. In particular, antimicrobials are added to soaps, 29 
cosmetics and disinfectants to protect against the growth of microorganisms, including bacteria, viruses 30 
and fungi. Some of these chemicals, their metabolites and/or their degradation products have been 31 
reported to be potentially bioaccumulative2, endocrine disrupting3, ecotoxic in aquatic ecosystems4 and 32 
leading to microbial resistance5,6. However very little is known about actual human exposure to 33 
antimicrobials in personal care products and therefore about the possibility to cause long term health 34 
effects. Even though available information concerning the percutaneous absorption of antimicrobials in 35 
humans is still scarce, it is known that some of them can be absorbed through the skin7, suggesting that 36 
exposure results mostly from topical application of personal care products. However, ingestion of 37 
contaminated food and water 8,9 and inhalation of indoor dust10 represent other important 38 
indirect/environmental sources of exposure. Antimicrobials can be metabolised in humans followed by 39 
excretion of parent compound and their metabolites primarily with urine. Because the presence of those 40 
compounds in blood, serum and urine has been demonstrated11–15 and their environmental persistence 41 
and widespread use documented, it is unsurprising that they can be found in wastewater and in the 42 
receiving environment16,17. Their omnipresence, potential for bioaccumulation and possible synergistic 43 
effects of mixtures  have raised public concern regarding their possible effects on human health as well 44 
as their role in the development of antimicrobial resistance18. There is therefore the need to consider a 45 
greater range of factors contributing to potential health effects of combined exposures within the risk 46 
assessment process. Risk assessment of mixtures is known to be difficult due to complexity of 47 
contributing factors when compared to the assessment of single chemicals19. New approaches towards 48 
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risk assessment and evaluation of public exposure to antimicrobial agents in personal care products are 49 
therefore critically needed. 50 
By comparing community levels of environmental stressors (both external and internal) with observed 51 
health effects, conclusions could be drawn as to whether elevated levels of certain chemicals could be 52 
linked with particular diseases. Such epidemiological studies are currently being undertaken via 53 
traditional approaches which use simple tools including case histories, questionnaires, or molecular 54 
epidemiology, which combines the above with sensitive laboratory techniques. These approaches 55 
monitor biological responses, rather than diseases in human populations through the usage of 56 
biomarkers20. However, a limitation of molecular epidemiology, due to logistical difficulties and high 57 
cost, is the restricted size of study groups and inability to gather comprehensive information on the 58 
complexity of combined (and cumulative) exposure to mixtures of chemicals and their effects. 59 
Therefore the community lacks robust measures that can be used to gather real-time information on 60 
community-wide health.  61 
Urban water fingerprinting for human metabolic biomarkers is a new approach in epidemiological 62 
exposure studies that can revolutionise the way we estimate public exposure to chemicals. This 63 
approach is also known wastewater based epidemiology (WBE). WBE is a new concept that aims to 64 
overcome the above limitations and to provide spatial and temporal near-real time estimation of 65 
community-wide exposure to wide range of chemicals. This unique approach assumes that 66 
epidemiological information can be retrieved from wastewater via the analysis of human metabolic 67 
biomarkers. Although still in its infancy, it is currently used to determine illicit drug use trends at the 68 
community level through the analysis of urinary biomarkers in wastewater21–23. This approach can be 69 
also extended to make a real time assessment of population health status24. WBE postulates that specific 70 
human metabolic biomarkers (e.g. characteristic metabolites of toxicants or pollutants) excreted with 71 
urine and faeces, and resulting from exposure to certain chemicals, are pooled by the urban wastewater 72 
system providing evidence of the amount and type of toxicants or pollutants to which a population 73 
contributing to the analysed water, has been exposed. Urban water fingerprinting can therefore provide 74 
anonymous and comprehensive estimation of the community-wide health status in near-real time. 75 
The selection of unique metabolic biomarkers that are characteristic for each individual chemical and 76 
route of exposure is a critical step in order to verify public exposure to these chemicals via WBE, e.g. 77 
in order to distinguish between internal and external exposure, and to account for direct disposal, since 78 
many sources contribute to chemicals being discharged into wastewater. Unfortunately, in the case of 79 
many chemicals, especially those that are not intended for human consumption (e.g. antimicrobials), 80 
there is no public knowledge of characteristic metabolic biomarkers that could be utilised in WBE. 81 
Nevertheless, due to their extensive use in personal care and consumer products25 dermal absorption is 82 
considered to be one of the main routes of human exposure. Understanding toxicokinetic process, 83 
including metabolism, is therefore crucial in the determination of toxicological effects and potential for 84 
bioaccumulation of these chemicals, as well as in the identification of biomarkers of exposure. Still, 85 
there are only a few studies which reported their in vivo or in vitro biotransformation. Wu, Liu and Cai 86 
(2010)15 investigated the metabolism of triclosan in vivo and in vitro. They observed both oxidative and 87 
phase II metabolites and identified glucuronidated triclosan as the major metabolite. Schebb et al. 88 
(2011)25 reported that the 0.6% circa of the amount of triclocarban present in bar soaps (70 ± 15 mg) 89 
was absorbed through the skin and that the 25% of total amount was excreted in urine almost exclusively 90 
as N-glucuronides. Unfortunately, most antimicrobials still remain hardly investigated.  91 
We are proposing a novel conceptual framework for identification of metabolic biomarkers via 92 
combined human metabolism and urban water fingerprinting assays. In this study, we identified, for the 93 
first time, human specific metabolites of the antimicrobial agent, 4-chloro-3-methylphenol (PCMC), as 94 
potential biomarkers of community-wide exposure to PCMC via WBE. This antimicrobial agent, also 95 
known as 4-chloro-m-cresol, is a phenolic compound  that has been proven to have an estrogenic activity 96 
determined by an in vitro yeast bioassay26. PCMC is also known to have an effect on Ca2+ homeostasis 97 
being a strong activator of the ryanodine receptors in the endoplasmic reticulum27 and to interfere with 98 
the thyroid hormone functions28. To the authors’ knowledge, there is no published data on metabolic 99 
pathways of PCMC in humans.  100 
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Experimental section 101 
Reagents and analytical standards 102 
Pooled human liver microsomes (HLM), S9 fraction pooled from human liver, β-nicotinamide adenine 103 
dinucleotide 2′-phosphate reduced (-NADPH ≥ 95%), Uridine 5′-diphosphoglucuronic acid trisodium 104 
salt (UDPGA 98-100%), alamethicin from Trichoderma viride (≥ 98%), 3′-phosphoadenosine 5′-105 
phosphosulphate lithium salt (PAPS ≥ 60%), 4-chloro-3-methylphenol (p-chlorocresol), potassium 106 
phosphate monobasic tetrasodium salt hydrate (KH2PO4), magnesium chloride hexahydrate (MgCl2), 107 
were purchased from Sigma-Aldrich (Gilligam,UK). The internal standard: 4-chloro-3-methylphenol-108 
2,6-d2, was purchased from QMX Laboratories Ltd.  109 
Solvents were of HPLC purity and were purchased from Sigma-Aldrich (Gilligam, UK). Stock standard 110 
solutions were prepared in methanol and stored in the dark at -20°C. 24h volume-proportional (100 mL 111 
every 15 minutes) composite wastewater influent samples were collected in PTFE bottles from a local 112 
wastewater treatment plant (WWTP) serving 70000 inhabitants on the 8th of June 2015. They were then 113 
transported to the laboratory in cool boxes packed with ice blocks and filtered through GF/F 0.7 µm 114 
glass fibre filter (Whatman, UK).  115 
In vitro assays for verification of metabolic profile of PCMC in humans 116 
Two in vitro assays were selected in this study: HLM and combined HLM and S9 fraction. Currently 117 
HLM represents the most commonly used in vitro model, providing an affordable way to give a good 118 
indication of the cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) 119 
metabolic profile 29. Unfortunately, the absence of other enzymes such as N-acetyltransferase (NAT), 120 
glutathione S-transferase (GST) and sulphotransferase (ST) implies, as a result, an incomplete range of 121 
metabolites being formed. A valid alternative to the use of HLM is the liver S9 fraction which contains 122 
both microsomal and cytosolic fractions (phase I and phase II metabolic enzymes) that lead to the 123 
formation of a range of metabolites giving, as a result, more representative metabolic profile when 124 
compared to HLM only. However, the overall amount of metabolites formed is lower due to lower 125 
enzyme activity in the S9 fraction when compared to microsomes. This might result in minor 126 
metabolites to remain unnoticed30. Therefore, in this paper, method development included different 127 
subcellular fractions (HLM and a combination of HLM and S9 fraction). 128 
In vitro HLM assay for verification of metabolic profile of PCMC. 10 µL of a phosphate buffer (50mM 129 
KH2PO4, pH 7.4, 5mM MgCl2), 10 µL of analyte solution (50 µM) were mixed with 10 µL human liver 130 
microsomes spiked with 1 µL of an alamethicin solution 12.5 mg/mL and 10 µL of a 100µM UDPGA 131 
solution. The reaction was initiated by addition of 10 µL of a 10 mM NADPH solution followed by 132 
incubation at 37°C for 1.5 h. After 1.5 h of incubation 10 µL of a 100µM PAPS solution were added 133 
and the incubation continued under the same conditions for 1.5 h. The negative controls with either no 134 
analyte or no HLM were incubated as described above to exclude all the non-enzymatic reactions. Each 135 
specific incubation was performed in duplicate. The reaction was quenched with 100 µL of acetonitrile 136 
ice cold, followed by centrifugation at 10000 rpm for 10 min (Centrifuge 5418, Eppendorf). The 137 
supernatant was removed and transferred to a new eppendorf tube and gently dried down by a stream 138 
of nitrogen at 40°C using TurboVap evaporator (Caliper, UK). The resulting residue was reconstituted 139 
with 50 µL of a 80:20 H2O:MeOH solution containing the internal standard (100 ng/mLM) and 140 
transferred into a polypropylene vial for analysis.   141 
All analyses were undertaken using a Dionex Ultimate 3000 HPLC (Thermo Fisher UK Ltd.) coupled 142 
with a Bruker Maxis HD Q-TOF (Bruker) equipped with an electrospray ionization source. Nitrogen 143 
was used as nebulising gas at a flow rate of 11 L/min at a temperature of 220°C and at a pressure of 3 144 
Bar. Capillary voltage was set at 4500 V and End Plate offset was set at 500 V. The analyses were 145 
performed in both positive and negative modes and acquisition was performed in both full scan mode 146 
(MS) and broadband CID acquisition mode (MS/MS). HyStar™ Bruker was used to coordinate the LC-147 
MS system. Chromatographic separation of the metabolites formed was achieved by using a WATERS 148 
ACQUITY UPLC BEH C18 column (50 mm x 2.1 mm, 1.7 µm) and the following mobile phase 149 
composition: 1 mM ammonium fluoride in water (A) and methanol (B). The gradient elution both in 150 
4 
 
ESI positive and negative mode was as follows: 5% B (0 -3 min) - 60% B (3 - 4 min) - 60% B (4 -14 151 
min), - 98% B (14 - 17 min) - 5% (17.1 - 20 min). The flow rate was kept constant at 0.4 ml/min and 152 
the column temperature was set at 40 °C. The source and operating parameters were optimized as 153 
follows: capillary voltage, 4500 V; dry gas temperature, 220 oC (N2); dry gas flow 12 L h−1 (N2); 154 
quadrupole collision energy, 4 eV; collision energy, 7 eV MS (full-scan analysis) and 20 eV MS/MS 155 
(bbCID mode).  Nitrogen was used as the nebulising, desolvation and collision gas.  The method was 156 
fully quantitatively validated for PCMC (intra-day, accuracy 120.2%, precision 2.4%; inter-day, 157 
accuracy 120.2%, precision 3.5%; IQL, 22 ng/L; IDL, 6.6 ng/L; linearity range, 0.07-27.5 mg/mL; R2 158 
0.9987; MDL, 0.013 ng/L; MQL, 0.045 ng/L).  159 
In vitro combined HLM/S9 fraction assay for verification of metabolic profile of PCMC Two 160 
incubation mixtures were prepared in duplicate by mixing 10 µL of phosphate buffer (50mM KH2PO4, 161 
pH 7.4, 5mM MgCl2), 10 µL of analyte solution (50µM), 10 µL of the100µM UDPGA solution and 10 162 
µL of HLM spiked with 1 µL of an alamethicin solution 12.5 mg/mL. The reaction was initiated by 163 
addition of 10 µL of a 10 mM NADPH solution followed by incubation at 37°C. The incubation was 164 
carried out for 3 h under the same conditions for three of the four samples. At 3 h 10 µL of S9 fraction 165 
and 10 µL the 100µM PAPS solution were added to the samples to be incubated for six h and incubation 166 
was continued. The negative controls with either no analyte or no enzymes were prepared as well for 167 
each time point. After quenching the reaction with 100 µL of acetonitrile ice cold, samples were 168 
prepared for analysis as described above.  169 
In vivo pooled urine assay 170 
Seven pooled urine samples were collected from a UK festival event. They came from five different 171 
urinals sampled on three different days. Solid phase extraction (SPE) was performed on pooled urine 172 
samples using HLB Oasis® cartridges Water, UK) to reduce the matrix effect and to concentrate each 173 
sample by 4-fold. SPE procedure was as follows: 2 mL of pooled urine were loaded onto Oasis HLB 174 
cartridges, which were preconditioned with 2 mL MeOH followed by 2 mL H2O. After loading, the 175 
cartridges were dried for 30 min and analytes were eluted with 4 mL MeOH. Extracts were then dried 176 
under a gentle nitrogen stream using a TurboVap evaporator (Caliper, UK, 40◦C). Dry extract was then 177 
reconstituted in 500 µL 80:20 H2O:MeOH, transferred to polypropylene vials and analysed using 178 
Dionex Ultimate 3000 HPLC coupled with a Bruker Maxis HD Q-TOF according to the procedure 179 
described above. 180 
Wastewater fingerprinting assay  181 
Raw wastewater samples collected from local wastewater treatment works, were filtered using GF/F  182 
glass microfibre filter 0.75 µm (Fisher Scientific, UK) followed by a solid phase extraction (SPE) using 183 
HLB Oasis® cartridges Water, UK) to reduce the matrix effect and to concentrate each sample by 400-184 
fold. SPE procedure was as follows: 100 mL of filtered wastewater were loaded onto Oasis HLB 185 
cartridges, which were preconditioned with 2 mL MeOH followed by 2 mL H2O. After loading, the 186 
cartridges were dried for 30 min and analytes were eluted with 4 mL MeOH. Extracts were then dried 187 
under a gentle nitrogen stream using a TurboVap evaporator (Caliper, UK, 40◦C). Dry extract was then 188 
reconstituted in 250 µL 80:20 H2O:MeOH, transferred to polypropylene vials and analysed using 189 
Dionex Ultimate 3000 HPLC coupled with a Bruker Maxis HD Q-TOF according to the procedure 190 
described above. 191 
After analysis, data extracted from the Bruker system were processed with MetID software (Advanced 192 
Chemistry Development, Inc., ACD/Labs, UK) in order to predict metabolite structures. However, the 193 
software predicts a large number of possible metabolites, of which a rather small number is actually 194 
observed in in vitro experiments. We therefore developed a systematic workflow as presented in Figure 195 
1 to limit false positive measurements.   196 
 197 
 198 
 199 
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Results and discussion 200 
In vitro assays 201 
The in vitro metabolism of PCMC catalysed by CYP and SULT enzymes has been investigated using 202 
a combination of pooled HLM an S9 fraction tests. Hydroxylation of un-substituted carbon atoms was 203 
expected to be the major biotrasformation reaction catalysed by CYPs whilst conjugations with phase 204 
II cofactors were expected to be the major reactions catalysed by UGT and ST. Phase II conjugations 205 
were expected to occur directly or following mono- and/or di-hydroxylation phase-I biotransformations.   206 
In vitro HLM assay. After incubating PCMC with HLM a number of peaks were detected using LCMS. 207 
Initial analysis of samples, performed using ACDLabs software, identified two potential metabolites. 208 
A representative extracted ion chromatogram (XIC) of PCMC metabolites detected are reported in Figs. 209 
S1 and S2. All samples were analysed in negative and in positive ionisation modes. However, all the 210 
potential metabolites had better intensity in the negative ionization mode. 211 
Incubation of PCMC produced a metabolite (m/z 157.0057) with elemental composition of the 212 
deprotonated molecule denoting C7H6ClO- (-3.6 ppm mass error) and a second one (m/z 317.0422) 213 
with elemental composition of the deprotonated molecule denoting C13H14ClO7- (-3.8 ppm mass 214 
error). ACDLabs analysis led to their identification as mono-hydroxylated metabolite (Fig S1b) and 215 
glucuronide conjugated (Fig. S2b). PCMC hydroxylate did not provide a distinctive fragmentation 216 
pattern in bbCID mode which necessitated MS/MS analysis. Fragmentation of ions with m/z 157.0062 217 
+/- 0.005 at 31 eV led to the formation of a fragment 121.0284 which corresponded with the loss of a 218 
chlorine moiety from the precursor ion (Fig. S1c). PCMC glucoronate instead produced in bbCID mode 219 
a fragment ion at m/z 141.0108 (C7H6ClO-, + 3.5 ppm mass error) that was assigned to [C6H8O6] loss, 220 
and was related to the presence of a glucuronate group (Fig. S2c, bottom). The fragments obtained 221 
confirmed the chemical structure of the metabolites. Additionally, two chlorine isotope peaks at m/z 222 
158.0086 and m/z 159.0024 (Fig. S1d) and at m/z 318.0452 and m/z 319.0390 (Fig. S2d) were observed. 223 
The peaks had small mass errors (<5 ppm) and their relative heights match those expected from a 224 
compound with one chlorine within 5% of the predicted abundance.  225 
PCMC metabolites have not been previously documented in literature, therefore the results of this study 226 
are of considerate importance. However, sulphate metabolites that were initially thought to be suitable 227 
as a biomarker were not detected in the in-vitro HLM assay. This could be due to two main factors. 228 
Firstly, the incubation time may not have been sufficiently long to allow detectable amounts of 229 
metabolites to be formed, as well as also not allowing the higher number of metabolites to be produced. 230 
Secondly this could be due to the lack of phase II enzymes being used such as sulphotransferases, of 231 
which HLM are deficient. To account for this, HLM/S9 fraction assay was undertaken (see below). 232 
In vitro combined HLM/S9 fraction assay. The in vitro combined HLM/S9 fraction assay included 233 
verification of quantitative and qualitative changes of metabolic profile in two time intervals (3 and 6 234 
h). Moreover, due to the addition of the S9 fraction to the incubation mixture, further metabolites 235 
(sulphate conjugated) were expected to be produced. Indeed, an incubation of PCMC with pooled 236 
HLM/S9 fraction produced two further metabolites: sulphated PCMC and mono-hydroxylated 237 
sulphated PCMC (Fig. 2 and S3).   238 
It can be seen in Fig. 2 that the in vitro test leads to the formation of a metabolite with retention time 239 
denoting 6.4 min (Fig. 2b, dark peak). This chromatographic peak was absent in the blank control (Fig. 240 
2a). Spectral analysis performed using ACDLabs software identified the compound to be a sulphated 241 
metabolite (m/z 220.9684). Elemental composition of the deprotonated molecule of the sulphated 242 
metabolite was assigned as C7H6ClO4S- (+ 1.3 ppm mass error). The fragment ion at m/z 141.0117 243 
(C7H6ClO-, + 3.6 ppm mass error) was assigned to [O3S] loss, and was related to the presence of a 244 
sulphate group (Fig. 2c, bottom). To further confirm that the fragment ion originates from the suspected 245 
metabolite its chromatogram was extracted. The resulting XIC produced a peak whose elution time 246 
matched perfectly with that of the suspected metabolite (Fig. 2b, light peak).  Additionally, the presence 247 
of two chlorine isotope peaks at m/z 221.9713 and m/z 222.9653 (Fig. 2d) was observed. The peaks 248 
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had small mass errors <5 ppm and their relative heights match those expected from a compound with 249 
one chlorine within 5% of the predicted abundance.  250 
The in vitro HLM/S9 fraction assay led to the formation of another PCMC metabolite with retention 251 
time of 6.3 min (Fig S3b, dark peak). This is the same chromatographic peak that was absent in the 252 
blank control (Fig. S3a). Spectral analysis performed using ACDLabs software identified the compound 253 
to be the sulphated and hydroxylated metabolite (m/z 236.9632). Elemental composition of the 254 
deprotonated molecule of the metabolite was assigned as C7H6ClO5S- (+ 1.3 ppm mass error). The 255 
fragment ion at m/z 157.0065 (C7H6ClO2-, + 1.9 ppm mass error) was assigned to [O3S] loss, and was 256 
related, as previously, to the presence of a sulphate group (Fig. S3c, bottom). To further confirm that 257 
the fragment ion originates from the suspected metabolite its chromatogram was extracted. The 258 
resulting XIC produced a peak whose elution time matched perfectly with that of the suspected 259 
metabolite (Fig. S3b, light peak). Also, as above, two chlorine isotope peaks at m/z 237.9664 and m/z 260 
238.9601 (Fig. S3d) were observed. The peaks had small mass errors <5 ppm and their relative heights 261 
matched those expected from a compound with one chlorine within 5% of the predicted abundance.  262 
Phase II cofactor (PAPS) was added after 3 h to the incubation mixture to permit all the possible phase 263 
I metabolites to form before conjugation with sulphate took place. This approach attempts to replicate 264 
what happens in a living cell, where generally (but not necessarily) phase I minor biotransformations 265 
occur in preparation for successive phase II conjugation. Results are summarised in Fig. S4. It can be 266 
seen from Fig. S4 that hydroxylated metabolites are preferentially formed after 3 h of incubation time 267 
(88.7% against 11.3% conjugation with glucuronic acid). The hydroxylated PCMC was still the most 268 
abundant biotransformation product (40% of the total metabolites produced circa) after 6 h of incubation 269 
time, although at this sampling point phase II metabolites accounted for 59.8% of all the metabolites 270 
produced. In particular amongst the three phase II biotransformation observed after 6 h direct sulphation 271 
seemed to be the preferential conjugation route accounting for more than 25% of total 272 
biotransformation.  273 
In summary, both HLM and HLM-S9 fraction assays allowed for the identification of metabolites that 274 
have not been previously documented in literature, although the latter assay allowed the identification 275 
of a higher number of metabolites due to the addition of the S9 fraction resulting in a more efficient 276 
sulphation. Moreover a two-step approach, which entails the addition of phase II enzymes and 277 
sulphation cofactor after 3 h permits the identification of all the phase I and II metabolites and 278 
conjugated metabolites, providing a wider range of biotransformation products. The formation of 279 
PCMC sulphate conjugates means also that a more efficient sulphate conjugation takes place in the 280 
HLM-S9 fraction assay, when compared to the HLM assay. All the identified metabolites are presented 281 
in Tab. 1. The table reports also elemental composition and the mass accuracy measured in the two in 282 
vitro assays and in a wastewater sample from a local wastewater treatment plant (WWTP) (see 283 
discussion below).  284 
In vivo pooled urine assay  285 
The in vivo pooled urine assay led to identification of only one metabolite of PCMC, sulphated PCMC 286 
(Tab. 1 and Fig. 3).  Interestingly, hydroxylated and glucuronated metabolites were not observed in 287 
analysed pooled urine samples. This is in contrast with in vitro assays where glucuronated, sulphated 288 
and hydroxylated metabolites were identified. 289 
In vivo wastewater fingerprinting assay  290 
The aim of the two in vitro assays was to select potential biomarkers of exposure to PCMC. However, 291 
as the ultimate goal of this study was to verify community-wide exposure to these chemicals, analysis 292 
of untreated wastewater samples serving large community of 70 thousand people was undertaken. The 293 
identification of biomarkers was based on the systematic workflow presented in Fig. 1. The compounds 294 
detected in wastewater are summarised in Tab. 1.  As expected, given the complexity of the matrix, 295 
mass accuracy measured was lower than that measured in in vitro studies but still within set limits, with 296 
mass error values between 5 and 10 ppm (Tab. 1).  297 
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In vivo wastewater fingerprinting assay resulted in the detection and identification of only one 298 
metabolite of PCMC, sulphated PCMC, in wastewater (Fig. 4). The loss of [O3S] deduced by TOF MS 299 
spectra has been crucial for justifying and suggesting possible chemical structures. Interestingly, 300 
hydroxylated and glucuronated PCMC were not observed in analysed wastewater samples. This is in 301 
line with results obtained for in vivo pooled urine assay and it confirms that in vitro studies, although 302 
informative, cannot serve as the only tool intended for selection of biomarkers of exposure. 303 
Conclusions 304 
This study proved that combined human metabolism and wastewater fingerprinting assay is a powerful 305 
tool to investigate human exposure to chemicals present in personal care products and a wider-group of 306 
chemicals that are not intended for human consumption and therefore lack comprehensive risk 307 
assessment data. We have proposed a robust systematic workflow that enables fast and comprehensive 308 
selection of characteristic biomarkers of public exposure to chemical substances (Fig. 1). The workflow 309 
consists of several steps: Step 1: In vitro HLM/S9 assay; Step 2: In vivo pooled urine assay; Step 3: In 310 
vivo wastewater fingerprinting assay; Step 4: Analysis with HR-MSMS; Step 5: Data processing and 311 
Step 6: Selection of biomarkers. In Step 4, after the establishment of a list of suspected metabolites 312 
using ACDLab software (Step 4a), in order to avoid false positives, their accurate mass, retention time 313 
and fragmentation pattern are examined (Step 4b,c,d). Finally the structure of the suspects is confirmed 314 
by investigating the MS/MS fragmentation pattern in bbCID mode (Step 4e). For those metabolites that 315 
do not provide an optimal MS/MS fragmentation pattern in bbCID mode, a further confirmation step 316 
performing a data-dependent MS/MS acquisition is required (Step 4f), i.e. an MS/MS analysis is 317 
triggered if a compound from a target ion list is detected. In contrast to targeted screening, non-target 318 
screening starts without any a priori information on the compounds to be detected. However, this study 319 
falls in between these two categories, since the chemically meaningful structures which can be assigned 320 
to an unknown peak are limited to structures showing a close relationship with the parent compound. 321 
Four new possible metabolites of PCMC (hydroxylated, glucuronidated, sulphated and hydroxylated & 322 
sulphated PCMC) were identified after in vitro HLM/S9 studies and were proposed as biomarkers of 323 
exposure. The absence of phase I metabolites in the presence of phase II cofactor PAPS suggested that 324 
sulphation was the preferential metabolic pathway for this compound. Only one of these metabolites 325 
(PCMC sulphated) was confirmed in wastewater and in urine suggesting human internal exposure to 326 
PCMC despite the fact that this compound is utilised in products meant for external use. Consequently 327 
to the results obtained in this present work it seems evident that the impact of the exposure to PCMC 328 
and other chemicals not intended for human consumption might need to be reconsidered. Also in a 329 
realistic overview of its impact on the aquatic ecosystem its identified metabolite should be also 330 
investigated to verify their potential environmental impact. 331 
The aim of this paper was to introduce a new assay for identification of new metabolic biomarkers in 332 
WBE. Further work will be undertaken to verify utility of selected biomarkers in a large urban water 333 
catchment monitoring campaign. 334 
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Figure S2 Detection and identification of PCMC glucuronate metabolite by UHPLC-QTOF-MS 353 
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high-energy (bbCID mode) spectra and structures of the metabolite and fragment ion observed. (d) XIC 362 
at m/z 236.9632, 237.9660 and 238.9601 for PCMC hydroxylate & sulphate and the two chlorine 363 
isotope peaks (top) and mass spectra (bottom). 364 
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over a 3 and 6 h incubation time. 366 
Report 1 Detection and identification of PCMC metabolites by UHPLC-QTOF-MS following in-vitro 367 
HLM assay. 368 
 Sample Name 4-Cl-3-Me_1_neg and PCMC_10ul_enz_B_Neg_2 XIC and mass spectrum of 369 
PCMC hydroxylated, PCMC glucuronidated, PCMC and relative isotopes following in-vitro 370 
HLM assay for verification of metabolic profile of PCMC. 371 
 Sample Name 4-Cl-3-Me_2_neg and PCMC_10ul_enz_B_Neg_2 XIC and mass spectrum of 372 
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Report 2 Detection and identification of PCMC metabolites by UHPLC-QTOF-MS following in-vitro 378 
HLM/S9 assay. 379 
 Sample Name S9_4-Cl-3-Me_A_6_Hour_Neg and 4_Cl_6hA_Neg XIC and mass spectrum of 380 
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9 
 
II metabolites), following in-vitro HLM/S9 assay (6 hour sampling point) for verification of 393 
metabolic profile of PCMC. (blank control) 394 
Report 3 Detection and identification of PCMC metabolite by UHPLC-QTOF-MS following urine 395 
analysis. 396 
 Sample Name Urine_141_A neg XIC and mass spectrum of PCMC sulfated (including bbCID 397 
fragmentation pattern) and relative isotopes, following direct in-vivo urine profiling assay. 398 
 Sample Name Urine_141_B neg XIC and mass spectrum of PCMC sulfated (including bbCID 399 
fragmentation pattern) and relative isotopes, following direct in-vivo urine profiling assay. 400 
Report 4 Detection and identification of PCMC metabolites by UHPLC-QTOF-MS following 401 
wastewater analysis. 402 
 Sample Name Inf day 1A neg XIC and mass spectrum of PCMC and PCMC sulphated 403 
(including bbCID fragmentation pattern) and relative isotopes. 404 
Report 5 MRM fragmentation pattern of PCMC standard solution. 405 
 Sample Name MRM_4Cl3MPox_Met2_STD_5 MRM fragmentation pattern of PCMC 406 
standard solution 407 
References 408 
(1)  Aiello, A. E.; Larson, E. L.; Levy, S. B. Clin. Infect. Dis. 2007, 45 Suppl 2, S137–S147. 409 
(2)  Dhillon, G. S.; Kaur, S.; Pulicharla, R.; Brar, S. K.; Cledón, M.; Verma, M.; Surampalli, R. Y. Int. J. 410 
Environ. Res. Public Health 2015, 12 (5), 5657–5684. 411 
(3)  Ahn, K. C.; Zhao, B.; Chen, J.; Cherednichenko, G.; Sanmarti, E.; Denison, M. S.; Lasley, B.; 412 
Pessah, I. N.; Kültz, D.; Chang, D. P. Y.; Gee, S. J.; Hammock, B. D. Environ. Health Perspect. 413 
2008, 116 (9), 1203–1210. 414 
(4)  Rostkowski, P.; Horwood, J.; Shears, J. A.; Lange, A.; Oladapo, F. O.; Besselink, H. T.; Tyler, C. R.; 415 
Hill, E. M. Environ. Sci. Technol. 2011, 45 (24), 10660–10667. 416 
(5)  Gautam, P.; Carsella, J. S.; Kinney, C. A. Water Res. 2014, 48 (1), 247–256. 417 
(6)  Aiello, A. E.; Marshall, B.; Levy, S. B.; Della-Latta, P.; Lin, S. X.; Larson, E. Emerg. Infect. Dis. 2005, 418 
11 (10), 1565–1570. 419 
(7)  Moss, T.; Howes, D.; Williams, F. M. Food Chem. Toxicol. 2000, 38 (4), 361–370. 420 
(8)  Loraine, G. a.; Pettigrove, M. E. Environ. Sci. Technol 2006, 40 (3), 687–695. 421 
(9)  Wu, X.; Ernst, F.; Conkle, J. L.; Gan, J. Environ. Int. 2013, 60, 15–22. 422 
(10)  Geens, T.; Roosens, L.; Neels, H.; Covaci, A. Chemosphere 2009, 76 (6), 755–760. 423 
(11)  Allmyr, M.; Harden, F.; Toms, L. M. L.; Mueller, J. F.; McLachlan, M. S.; Adolfsson-Erici, M.; 424 
Sandborgh-Englund, G. Sci. Total Environ. 2008, 393 (1), 162–167. 425 
(12)  Heffernan, A. L.; Baduel, C.; Toms, L. M. L.; Calafat, A. M.; Ye, X.; Hobson, P.; Broomhall, S.; 426 
Mueller, J. F. Environ. Int. 2015, 85, 77–83. 427 
(13)  Asimakopoulos, A. G.; Thomaidis, N. S.; Kannan, K. Sci. Total Environ. 2014, 470, 1243–1249. 428 
(14)  Ye, X.; Zhou, X.; Furr, J.; Ahn, K. C.; Hammock, B. D.; Gray, E. L.; Calafat, A. M. Toxicology 2011, 429 
286 (1-3), 69–74. 430 
(15)  Wu, J.; Liu, J.; Cai, Z. 2010, 1828–1834. 431 
(16)  Kumar, B.; Verma, V. K.; Sharma, C. S.; Akolkar, A. B. J. Xenobiotics 2014, 4 (1), 46–52. 432 
10 
 
(17)  Coogan, M. a; La Point, T. W. Environ. Toxicol. Chem. 2008, 27 (8), 1788–1793. 433 
(18)  Yazdankhah, S. P.; Scheie, A. a; Høiby, E. A.; Lunestad, B.-T.; Heir, E.; Fotland, T. Ø.; Naterstad, 434 
K.; Kruse, H. Microb. Drug Resist. 2006, 12 (2), 83–90. 435 
(19)  Silins, I.; Högberg, J. Int. J. Environ. Res. Public Health 2011, 8 (3), 629–647. 436 
(20)  Chen, C.; Kostakis, C.; Gerber, J. P.; Tscharke, B. J.; Irvine, R. J.; White, J. M. Sci. Total Environ. 437 
2014, 487, 621–628. 438 
(21)  Daughton, C. G. Sci. Total Environ. 2012, 414, 6–21. 439 
(22)  Baker, D. R.; Barron, L.; Kasprzyk-Hordern, B. Sci. Total Environ. 2014, 487 (1), 629–641. 440 
(23)  Yang, Z.; Castrignanò, E.; Estrela, P.; Frost, C. G.; Kasprzyk-Hordern, B. Sci. Rep. 2016, 6 (October 441 
2015), 21024. 442 
(24)  Reid, M. J.; Thomas, K. V. Environ. Sci. Technol. 2011, 45 (18), 7611–7612. 443 
(25)  Schebb, N. H.; Inceoglu, B.; Ahn, K. C.; Morisseau, C.; Gee, S. J.; Hammock, B. D. 2011, 3109–444 
3115. 445 
(26)  Miller, D.; Wheals, B. B.; Beresford, N.; Sumpter, J. P. Environ. Health Perspect. 2001, 109 (2), 446 
133–138. 447 
(27)  Ortopedico, O.; San, D. H.; Scientific, R. . 448 
(28)  Ghisari, M.; Bonefeld-Jorgensen, E. C. Toxicol. Lett. 2009, 189 (1), 67–77. 449 
(29)  Ballesteros-Gómez, A.; Erratico, C. a; Eede, N. Van Den; Ionas, A. C.; Leonards, P. E. G.; Covaci, 450 
A. Toxicol. Lett. 2014, 232 (1), 203–212. 451 
(30)  Brandon, E. F. a; Raap, C. D.; Meijerman, I.; Beijnen, J. H.; Schellens, J. H. M. Toxicol. Appl. 452 
Pharmacol. 2003, 189 (3), 233–246. 453 
  454 
11 
 
Table 1 PCMC and their metabolic biomarkers.  455 
 456 
457 
   In-vitro HLM 
assay   
In-vitro HLM/S9 
fraction assay 
In-vivo pooled 
urine assay 
In-vivo 
wastewater 
fingerprinting 
assay 
Compound Elemental 
composition 
[M-H]- 
Exact 
mass  
(m/z) 
Peak top 
mass 
(m/z) 
Mass 
error 
(ppm) 
Peak top 
mass 
(m/z) 
Mass 
error 
(ppm) 
Peak top 
mass 
(m/z) 
Mass 
error 
(ppm) 
Peak top 
mass 
(m/z) 
Mass 
error 
(ppm) 
PCMC C7H6ClO
- 141.0113 141.0118 +3.6 141.0116 +2.1 - - 141.0122 +6.0 
PCMC hydroxylated C7H6ClO2
- 157.0062 157.0049 -8.2 157.0061 -0.6  - - - - 
PCMC glucuronidated C13H15ClO7
- 317.0434 317.0422 -3.8 317.0442 +2.5 - - - - 
PCMC sulphated C7H6ClO4S
- 220.9681 - - 220.9684 +1.3 220.9670 - 5 220.9695 +6.4 
PCMC hydroxylated 
& sulphated 
C7H6ClO5S
- 236.9630 - - 236.9632 +0.9 - - - - 
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Figure 1 A systematic workflow for verifying human exposure to chemicals via combined in-
vitro HLM/S9 and in-vivo pooled urine and wastewater profiling assay 
  
13 
 
 
 
Figure 2 Detection and identification of sulphated PCMC by UHPLC-QTOF-MS following in-
vitro HLM/S9 assay. XICs at m/z 220.9681 and 141.0113 (0.005-Da mass-window width) for 
analyte-sample (b) and control-sample (a). (c) (top) Low-energy (full-scan analysis) and 
(bottom) high-energy (bbCID mode) spectra and structures of the metabolite and fragment ion 
observed. (d) XIC at m/z 220.9684, 221.9713 and 222.9653 for PCMC sulphate and the two 
chlorine isotope peaks (top) and mass spectra (bottom). 
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(a)
(b)
(c)
(d)6.4 min
min
m/z
14 
 
 
Figure 3 Detection and identification of sulphated PCMC by UHPLC-QTOF-MS following in-
vivo poled urine assay.  (a) XICs at m/z 220.9681 and 141.0113 (0.005-Da mass-window 
width). (b) (top) Low-energy (full-scan analysis) and (bottom) high-energy (bbCID mode) 
spectra and structures of the metabolite and fragment ion observed. (c) XIC at m/z 220.9670, 
221.9698 and 222.9640 (0.005-Da mass-window width) for PCMC and the two chlorine 
isotope peaks (top) and mass spectra (bottom). 
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Figure 4 Detection and identification of sulphated PCMC by UHPLC-QTOF-MS following in-
vivo wastewater profiling assay.  (a) XICs at m/z 220.9681 and 141.0113 (0.005-Da mass-
window width). (b) (top) Low-energy (full-scan analysis) and (bottom) high-energy (bbCID 
mode) spectra and structures of the metabolite and fragment ion observed. (c) XIC at m/z 
220.9695, 221.9724 and 222.9664 (0.005-Da mass-window width) for PCMC and the two 
chlorine isotope peaks (top) and mass spectra (bottom). 
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